DR. DOPING

Instructions

Logo DR. DOPING

Instructions / Instruction for use: CI-KLIM

I want this, give me price

ATX code G02CX Preparations for the treatment of gynecological diseases others

Pharmacological group

Estrogens, gestagens; Their homologues and antagonists

Nosological classification (ICD-10)

N95.1 menopausal and menopausal status of women

Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause

Composition

Tablets, coated with a coating.

active substance:

Tsimitsifugi extract dry with the content of the sum of triterpene glycosides in terms of 27-deoxyactein 2.5% 0.02 g

Excipients

Core: MCC - 0.145 g; Potato starch - 0.055 g; Calcium stearate - 0.0019 g; Silicon dioxide colloidal - 0,0011 g

Shell: hypromellose (E464, hydroxypropylmethylcellulose) - 0.0035 g; Titanium dioxide (E171) 0.0015 g; Polysorbate 80 (Tween 80) 0.001 g; Macrogol-400 (E1521, polyethylene glycol-400) - 0.0007 g; Iron dye oxide red - 0.0002 g; Ferric oxide brown oxide (ferronate) 0.0001 g

Description of dosage form

Tablets: round, biconcave, covered with a coat of pure pink to pink with a brown tint, with a specific smell.

pharmachologic effect

The pharmacological action is estrogen-like.

Pharmacodynamics

CI-KLIMŪ has an estrogen-like effect, exhibits sedative properties, has a positive therapeutic effect on the autonomic nervous system.

CI-KLIMŪ reduces levels of FSH and LH, increases the level of estradiol, which leads to the elimination of early climacteric disorders (psychoemotional and vegetovascular disorders) and delayed climacteric disorders associated with a decreased level of estrogen.

The therapeutic effect of CI-KLIMŪ drug develops gradually and manifests itself after approximately 2-4 weeks of treatment.

Indications

Vegetative-vascular and psychoemotional disorders in pre-, post- and menopause (including hot flashes, excessive sweating, sleep disturbances, increased nervous excitability, mood changes, apathy);

Disorders associated with a decrease in the level of estrogen during the menopause.

Contraindications

Hypersensitivity to the components of the drug;

Estrogen-dependent tumors.

With caution: violations of the liver; epilepsy; Diseases and brain trauma (use is possible only after consulting a doctor).

pregnancy and lactation

The drug should not be used during pregnancy and lactation.

Side effects

Allergic reactions to the drug components are possible. In rare cases, there may be pain in the epigastric region and an increase in body weight.

Interaction

In connection with the possibility of overdose it is not recommended to take with other preparations containing tsimitsifugi extract.

Dosing and Administration

Inside, 1 tab. (Not liquid, squeezed a small amount of liquid) 2 times a day, if possible at the same time of day (morning and evening). The duration of treatment is determined by the doctor.

Overdose

Symptoms: with occasional use of the drug in doses that are significantly higher than recommended, dyspepsia, gastralgia, and liver dysfunction may be observed.

Treatment: symptomatic.

special instructions

Without consulting a doctor, the drug should not be taken more than 3 months.

When changing the nature of the menstrual cycle, as well as with prolonged or other newly arising complaints, you should consult a doctor.

When pregnancy occurs, stop taking the drug and consult a doctor.

Influence on the ability to drive vehicles and work with machinery. The drug in recommended doses does not affect the ability to drive a car and work with machines.

Form of issue

The tablets covered with a cover, 20 mg. In a polymer bank for 30, 40, 60 or 90 pcs. 1 bank in a pack of cardboard. In the outline of the cell packaging of PVC film and aluminum foil of 20 pcs. 1, 2, 3 or 4 contour squares in a pack of cardboard.

Terms of leave from pharmacies

Without recipe.

storage Conditions

In dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.

Someone from the United Kingdom - just purchased the goods:
Sextaphag 20ml 4 vials